Lpl Financial LLC Rigel Pharmaceuticals Inc Transaction History

Lpl Financial LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.12 - $1.57 $33 - $47	30 Added 0.1%	30,223 $44,000
Q4 2023 Feb 14, 2024	BUY	$0.72 - $1.56 $2,172 - $4,708	3,018 Added 11.11%	30,193 $43,000
Q4 2022 Feb 07, 2023	SELL	$0.67 - $11.9 $757 - $13,447	-1,130 Reduced 3.99%	27,175 $40,000
Q3 2022 Nov 14, 2022	SELL	$1.1 - $12.2 $8,451 - $93,732	-7,683 Reduced 21.35%	28,305 $33,000
Q4 2021 Feb 14, 2022	BUY	$2.36 - $3.57 $24,591 - $37,199	10,420 Added 40.75%	35,988 $95,000
Q3 2021 Nov 15, 2021	BUY	$3.5 - $4.5 $33,180 - $42,660	9,480 Added 58.93%	25,568 $93,000
Q2 2021 Aug 13, 2021	BUY	$3.09 - $4.54 $49,711 - $73,039	16,088 New	16,088 $70,000
Q1 2020 May 14, 2020	SELL	$1.27 - $3.0 $14,605 - $34,500	-11,500 Closed	0 $0
Q2 2019 Aug 09, 2019	SELL	$2.02 - $2.61 $4,040 - $5,220	-2,000 Reduced 14.81%	11,500 $30,000
Q4 2018 Feb 07, 2019	BUY	$2.08 - $3.36 $4,160 - $6,720	2,000 Added 17.39%	13,500 $31,000
Q2 2018 Aug 14, 2018	BUY	$2.83 - $4.11 $32,545 - $47,265	11,500 New	11,500 $33,000

335K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $3.72B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Lpl Financial LLC with notifications on news.